Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and/or BCL6 Rearrangements.

Burkitt lymphoma (BL) is highly aggressive and requires very intensive chemotherapy approaches for successful treatment. Although "standard" approaches are tolerated in young patients, this is not the case in older adults, and new approaches that lower toxicity but maintain high curability are needed and are currently in development. Recently, high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements have been categorized separately from diffuse large B-cell lymphoma or BL. These have poor outcomes and many exciting novel approaches are being tested in an attempt to augment curability. These diseases harbor many interesting targets for rational small molecule inhibition in future trials.